Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.37 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.37 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.37 |
| ▸ | TK2 | O00142 | 3/20 | 0.37 |
| ▸ | TOP2A | P11388 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29703065 | 0.89 | TK1 (0.36) | TK1NT5MRNASE1TK2 | |
| SCHEMBL4580937 | 0.87 | NT5M (0.41) | TK1NT5MRNASE1 | |
| SCHEMBL8931976 | 0.86 | TK1 (0.38) | TK1NT5MRNASE1TOP2A | |
| SCHEMBL7900375 | 0.85 | TK1 (0.40) | TK1NT5MRNASE1 | |
| SCHEMBL8932077 | 0.81 | TK1 (0.36) | TK1 | |
| SCHEMBL6829895 | 0.81 | TK1 (0.34) | TK1TK2TOP2A | |
| SCHEMBL7199105 | 0.80 | TYMP (0.35) | TK1NT5MRNASE1TK2 | |
| SCHEMBL9014399 | 0.80 | NT5M (0.43) | TK1NT5MRNASE1TK2 | |
| SCHEMBL8931967 | 0.79 | RNASE1 (0.37) | TK1NT5MRNASE1TK2TOP2A | |
| SCHEMBL2113756 | 0.79 | TK1 (0.42) | TK1NT5MRNASE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559517-B2 | Oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20220235090-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2022-07-28 | — | — | US | disclosed |
| US-20180291056-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2018-10-11 | — | — | US | disclosed |
| US-5681940-A | CONTAIN TETRAHYDROTHIOPHENE OR PYROLIDINE RINGS | ICN PHARMACEUTICALS (US) | 1997-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235090-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | RNGTT, IGF2BP2, DCLRE1B | TK1 110/4885NT5M 2153/4885RNASE1 86/4885 |
| US-20180291056-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | RNGTT, IGF2BP2, DCLRE1B | TK1 110/4885NT5M 2153/4885RNASE1 86/4885 |
| US-12559517-B2 | Oligonucleotide manufacturing method | POLL, IGF2BP1, POLI | TK1 48/4885NT5M 1584/4885RNASE1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.